PLIVA launches risperidone, paroxetine and torasemide

PLIVA d.d. ("PLIVA") is pleased to announce that it has launched a generic version of risperidone in Poland, under the trademark Risset. Risperidone is a drug for the treatment of psychotic disorders and symptoms such as hallucination, delusions and hostility. PLIVA's Risset is sold at a more affordable price than the original drug, benefiting both patients and state budget. The recently introduced legislation on therapeutic substitution has resulted in a positive early off-take of the product. According to IMS data for 2002, sales of risperidone reached US$ 23.1 m in Poland.

Zagreb, 11 July 2003



With 90 years of successful pharmaceutical experience, PLIVA is today a member of the Teva Group, one of the largest pharmaceutical companies in the world. We at PLIVA are dedicated to providing our customers with high quality, affordable medicines for a better quality of life.

Read more


As a responsible corporate citizen, PLIVA makes considerable investments in the communities in which it operates via its charitable donations program and public health actions, which directly contribute to healthcare improvement.

Read more